Baxter names José Almeida chairman and chief executive
pharmafile | October 29, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Joe Almeida, José Almeida, baxter
Baxter has named José (Joe) Almeida as the company’s new chairman and chief executive from January 1, 2016. Almeida will join the company immediately as an executive officer to facilitate a smooth leadership transition.
Almeida, 53, will succeed Robert L Parkinson Jr, who has served as the company’s chairman and chief executive since 2004. Parkinson will retire from these roles on the same date that Almeida commences, with a brief transition period thereafter. Upon retirement, Parkinson will assume the title of chairman emeritus.
Parkinson says: “Joe brings to Baxter tremendous experience in the global medical products marketplace, and has a demonstrated record of improving profitability and creating value for all stakeholders. His deep understanding of the complex global supply chain will be a great strength for the company as he oversees a broad portfolio of medically necessary products across a geographically expansive marketplace. What Joe brings to Baxter in skill and experience is imperative to the company’s stated goal of accelerating profitable growth over the near and long term.”
Almeida served as chairman, president and chief executive of Covidien from 2012 through 2015 and was named a director of the company in 2011. Prior to this appointment, Almeida was president of its medical devices organisation. In this position, he oversaw several businesses accounting for approximately two-thirds of the company’s total annual revenues and approximately three-quarters of its operating profit.
In addition to Covidien, Almeida held leadership positions at Wilson Greatbatch Technologies, American home products’ Acufex Microsurgical division, and Johnson & Johnson’s professional products division. He began his career as a management consultant at Andersen Consulting (Accenture).
“Baxter is a trusted and admired brand in healthcare. The foundational mission of Baxter to save and sustain lives is at the centre of the company’s ability to endure, serving the needs of healthcare providers and patients for more than 80 years,” says Almeida. “Leading the company as it emerges from the spinoff of Baxalta presents an outstanding opportunity to create value and further the company’s mission.”
“We are extremely pleased for Joe to assume the leadership role at Baxter and carry forward important growth initiatives underway, while creating new opportunities to unleash value,” says Thomas Stallkamp, lead independent director of Baxter. “Joe has more than 24 years of global healthcare experience and an outstanding record of results and clear alignment to our strategy and culture, which led the board to unanimously endorse him as the right leader for the company. We also owe our gratitude to Bob Parkinson, whose leadership, integrity and vision have transformed and prepared Baxter for sustained success.”
Related Content
Baxter expands US portfolio with new injectables
Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of …
Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care
American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a …
Baxter hikes 2016 earnings view driven by strong Q1 results
Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. …
